EIF2AK3 and melanoma: To evaluate whether PERK is involved in the regulation of resistance to BRAFi in melanoma, we first tested the ability of a PERK inhibitor GSK2606414 (PERKi)36 to block cell proliferation (viability) of BRAFi-resistant melanoma compared with the treatment of BRAFi.